Bowden, Michaela
Nadal, Rosa
Zhou, Chensheng W.
Werner, Lillian
Barletta, Justine
Juanpere, Nuria
Lloreta, Josep
Hernandez-LlodrĂ , Silvia
Morote, Juan
de Torres, Ines
Orsola, Anna
Cejas, Paloma
Long, Henry
Bellmunt, Joaquim
Article History
Received: 24 March 2020
Accepted: 20 October 2020
First Online: 18 November 2020
Competing interests
: M. Bowden and J. Bellmunt have applied for a patent based on the genomic findings for the diagnosis and/or the prediction of the progression of high grade T1 micropapillary bladder cancer. The method comprises quantifying the expression product of each one of FABP3, CD36 and RAET1E genes in an isolated sample from the subject. The analysis of these 3 differentially expressed genes (FABP3, CD36 and RAET1E) allowed to create a risk index that could help to identify patients with micropapillary variant of high grade T1 with a higher risk of progression. The other authors do not have any conflicts of interest to declare.